FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy GlobeNewswire August 11, 2025 NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, is […]